Close Menu

Genalyte

Still Going for Small

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

The company said this week that is has raised $36 million in funding, as it continues efforts to develop its Maverick platform for rapid testing in doctors' offices.

The company said it will use the funds to further refine its Maverick Detection System for rapid blood testing in outpatient settings like doctors' offices.

The company is preparing a clinical study through which it will collect data that it will use to submit the device to FDA for 510(k) clearance next year.

The San Diego diagnostics firm's technology is designed for rapid, multiplexed, blood-based testing in a physician's office setting.

Three collaborators will further explore the clinical usefulness of a TAA panel in early cancer detection and measuring response to cancer immunotherapy.

The test would allow healthcare workers to differentiate Ebola from other diseases that mimic the virus, a trait which presented problems during the recent crisis in West Africa. 

NEW YORK (GenomeWeb News) – The National Cancer Institute has awarded Genalyte a $1 million Small Business Innovation Research grant to develop a biomarker panel to profile tumor antigen-associated antibodies, Genalyte said today.

After announcing last month the release of its type 1 diabetes antigen panel, Genalyte is now planning to develop an expanded version of the research-use assay with collaborators at the University of Colorado's Barbara Davis Diabetes Center.

Biognosys has launched a new spectral library generation service designed to build spectral libraries for use with data-independent acquisition mass spec techniques like SWATH.

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.